Novoclem Presents Promising New Data At The North America Cystic Fibrosis Conference on November 2, 2017

In vitro assays show that BIOC51 is bactericidal against nine of the most prevalent pathogens that cause cystic fibrosis lung infections

Novoclem Therapeutics, a biotech company focused on advancing novel nitric oxide therapies for the treatment of respiratory diseases, today announced that data from an in vitro study with its lead inhalable drug candidate, BIOC51, will be presented at the 2017 North American Cystic Fibrosis Conference (“NACFC”) being held November 2-4, in Indianapolis, IN.